DK2497780T3 - TDF-related compounds and analogs thereof - Google Patents

Info

Publication number

DK2497780T3

DK2497780T3 DK12171205.3T DK12171205T DK2497780T3 DK 2497780 T3 DK2497780 T3 DK 2497780T3 DK 12171205 T DK12171205 T DK 12171205T DK 2497780 T3 DK2497780 T3 DK 2497780T3

Authority

DK

Denmark

Prior art keywords

tdfrp

compound

compounds

cells

polypeptide

Prior art date

2005-09-20

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 592
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 289
• 238000000034 method Methods 0.000 claims description 201
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 90
• 230000014509 gene expression Effects 0.000 claims description 85
• 235000001014 amino acid Nutrition 0.000 claims description 75
• 150000001413 amino acids Chemical class 0.000 claims description 68
• 230000004069 differentiation Effects 0.000 claims description 57
• 238000011282 treatment Methods 0.000 claims description 53
• 201000010099 disease Diseases 0.000 claims description 52
• 239000000523 sample Substances 0.000 claims description 51
• 239000000203 mixture Substances 0.000 claims description 40
• 238000012360 testing method Methods 0.000 claims description 39
• 208000035475 disorder Diseases 0.000 claims description 35
• 239000003814 drug Substances 0.000 claims description 22
• 238000004519 manufacturing process Methods 0.000 claims description 20
• 150000003573 thiols Chemical class 0.000 claims description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims description 10
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
• 238000000576 coating method Methods 0.000 claims description 8
• 239000011248 coating agent Substances 0.000 claims description 7
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 150000001412 amines Chemical class 0.000 claims description 6
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
• 239000013068 control sample Substances 0.000 claims description 6
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
• 125000000542 sulfonic acid group Chemical group 0.000 claims description 5
• 102000001189 Cyclic Peptides Human genes 0.000 claims description 2
• 108010069514 Cyclic Peptides Proteins 0.000 claims description 2
• 230000008859 change Effects 0.000 claims description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 240
• 229920001184 polypeptide Polymers 0.000 description 220
• 210000004027 cell Anatomy 0.000 description 200
• 210000001519 tissue Anatomy 0.000 description 123
• -1 vaccines Substances 0.000 description 112
• 102000005962 receptors Human genes 0.000 description 105
• 108020003175 receptors Proteins 0.000 description 105
• 230000027455 binding Effects 0.000 description 89
• 241001465754 Metazoa Species 0.000 description 87
• 229940024606 amino acid Drugs 0.000 description 81
• 230000000694 effects Effects 0.000 description 72
• 150000007523 nucleic acids Chemical class 0.000 description 55
• 108020004414 DNA Proteins 0.000 description 51
• 108090000623 proteins and genes Proteins 0.000 description 47
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 45
• 229960004316 cisplatin Drugs 0.000 description 45
• 238000003556 assay Methods 0.000 description 43
• 210000003734 kidney Anatomy 0.000 description 42
• 102000039446 nucleic acids Human genes 0.000 description 42
• 108020004707 nucleic acids Proteins 0.000 description 42
• 230000004927 fusion Effects 0.000 description 40
• 239000012634 fragment Substances 0.000 description 39
• 239000013598 vector Substances 0.000 description 39
• 239000013604 expression vector Substances 0.000 description 38
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 37
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 37
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 35
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 32
• 239000002953 phosphate buffered saline Substances 0.000 description 32
• 230000006378 damage Effects 0.000 description 30
• 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 29
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 29
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 29
• 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 29
• 239000003153 chemical reaction reagent Substances 0.000 description 29
• 229940112869 bone morphogenetic protein Drugs 0.000 description 28
• 241000700159 Rattus Species 0.000 description 27
• 210000002966 serum Anatomy 0.000 description 26
• 108020004999 messenger RNA Proteins 0.000 description 25
• 239000003446 ligand Substances 0.000 description 24
• 230000001105 regulatory effect Effects 0.000 description 24
• 239000000126 substance Substances 0.000 description 24
• 125000005647 linker group Chemical group 0.000 description 22
• 201000002327 urinary tract obstruction Diseases 0.000 description 22
• 230000006907 apoptotic process Effects 0.000 description 21
• 239000003085 diluting agent Substances 0.000 description 21
• 208000014674 injury Diseases 0.000 description 21
• 239000000243 solution Substances 0.000 description 21
• SXGMVGOVILIERA-UHFFFAOYSA-N 2,3-diaminobutanoic acid Chemical compound CC(N)C(N)C(O)=O SXGMVGOVILIERA-UHFFFAOYSA-N 0.000 description 20
• 238000002360 preparation method Methods 0.000 description 20
• 125000006239 protecting group Chemical group 0.000 description 20
• 239000011534 wash buffer Substances 0.000 description 20
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 19
• 206010016654 Fibrosis Diseases 0.000 description 19
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 19
• 230000015572 biosynthetic process Effects 0.000 description 19
• 238000001514 detection method Methods 0.000 description 19
• 230000026731 phosphorylation Effects 0.000 description 19
• 238000006366 phosphorylation reaction Methods 0.000 description 19
• 125000003275 alpha amino acid group Chemical group 0.000 description 18
• 238000003786 synthesis reaction Methods 0.000 description 18
• 230000009261 transgenic effect Effects 0.000 description 18
• 208000027418 Wounds and injury Diseases 0.000 description 17
• 239000000556 agonist Substances 0.000 description 17
• 238000000338 in vitro Methods 0.000 description 17
• 230000003589 nefrotoxic effect Effects 0.000 description 17
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 16
• 239000012472 biological sample Substances 0.000 description 16
• 230000004761 fibrosis Effects 0.000 description 16
• 208000017169 kidney disease Diseases 0.000 description 16
• 231100000381 nephrotoxic Toxicity 0.000 description 16
• 230000008569 process Effects 0.000 description 16
• 239000005557 antagonist Substances 0.000 description 15
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 230000001939 inductive effect Effects 0.000 description 15
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 15
• 238000002965 ELISA Methods 0.000 description 14
• 206010028980 Neoplasm Diseases 0.000 description 14
• 206010060862 Prostate cancer Diseases 0.000 description 14
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 14
• 206010061481 Renal injury Diseases 0.000 description 14
• 230000004071 biological effect Effects 0.000 description 14
• 210000000988 bone and bone Anatomy 0.000 description 14
• 230000001413 cellular effect Effects 0.000 description 14
• 238000005859 coupling reaction Methods 0.000 description 14
• 238000002474 experimental method Methods 0.000 description 14
• 230000003993 interaction Effects 0.000 description 14
• 239000000463 material Substances 0.000 description 14
• 239000002609 medium Substances 0.000 description 14
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 14
• 101710120271 Bone morphogenetic protein receptor type-1B Proteins 0.000 description 13
• 108091028043 Nucleic acid sequence Proteins 0.000 description 13
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 13
• 108700019146 Transgenes Proteins 0.000 description 13
• 230000004913 activation Effects 0.000 description 13
• 210000004413 cardiac myocyte Anatomy 0.000 description 13
• 229940079593 drug Drugs 0.000 description 13
• 230000012010 growth Effects 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 13
• 238000010647 peptide synthesis reaction Methods 0.000 description 13
• 229960001052 streptozocin Drugs 0.000 description 13
• 230000001225 therapeutic effect Effects 0.000 description 13
• 239000003981 vehicle Substances 0.000 description 13
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
• 230000001684 chronic effect Effects 0.000 description 12
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
• 230000004054 inflammatory process Effects 0.000 description 12
• 238000000746 purification Methods 0.000 description 12
• 238000003259 recombinant expression Methods 0.000 description 12
• 238000012216 screening Methods 0.000 description 12
• 230000019491 signal transduction Effects 0.000 description 12
• 150000003384 small molecules Chemical class 0.000 description 12
• 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 11
• 101710120270 Bone morphogenetic protein receptor type-1A Proteins 0.000 description 11
• 241000699670 Mus sp. Species 0.000 description 11
• 108020004511 Recombinant DNA Proteins 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 230000024245 cell differentiation Effects 0.000 description 11
• 230000008878 coupling Effects 0.000 description 11
• 238000010168 coupling process Methods 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 239000003550 marker Substances 0.000 description 11
• 239000011159 matrix material Substances 0.000 description 11
• 210000000056 organ Anatomy 0.000 description 11
• 239000002245 particle Substances 0.000 description 11
• PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 10
• 206010061216 Infarction Diseases 0.000 description 10
• 206010061218 Inflammation Diseases 0.000 description 10
• 108090001005 Interleukin-6 Proteins 0.000 description 10
• 102000004889 Interleukin-6 Human genes 0.000 description 10
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
• 125000000539 amino acid group Chemical group 0.000 description 10
• 230000002424 anti-apoptotic effect Effects 0.000 description 10
• 125000003118 aryl group Chemical group 0.000 description 10
• 201000011510 cancer Diseases 0.000 description 10
• 239000001963 growth medium Substances 0.000 description 10
• 230000007574 infarction Effects 0.000 description 10
• 229940100601 interleukin-6 Drugs 0.000 description 10
• 208000028867 ischemia Diseases 0.000 description 10
• 239000002773 nucleotide Substances 0.000 description 10
• 125000003729 nucleotide group Chemical group 0.000 description 10
• 102000040430 polynucleotide Human genes 0.000 description 10
• 108091033319 polynucleotide Proteins 0.000 description 10
• 239000002157 polynucleotide Substances 0.000 description 10
• 206010003694 Atrophy Diseases 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 230000001594 aberrant effect Effects 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 230000037444 atrophy Effects 0.000 description 9
• 230000000903 blocking effect Effects 0.000 description 9
• 239000000872 buffer Substances 0.000 description 9
• 239000012707 chemical precursor Substances 0.000 description 9
• 229940088598 enzyme Drugs 0.000 description 9
• 230000006698 induction Effects 0.000 description 9
• 230000001404 mediated effect Effects 0.000 description 9
• 239000007790 solid phase Substances 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 239000000758 substrate Substances 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 8
• 102000004890 Interleukin-8 Human genes 0.000 description 8
• 108090001007 Interleukin-8 Proteins 0.000 description 8
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 8
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 8
• 239000004472 Lysine Substances 0.000 description 8
• 101100369074 Tuber dryophilum TDF-1 gene Proteins 0.000 description 8
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 8
• 230000002238 attenuated effect Effects 0.000 description 8
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
• 208000033679 diabetic kidney disease Diseases 0.000 description 8
• 238000010790 dilution Methods 0.000 description 8
• 239000012895 dilution Substances 0.000 description 8
• 239000002158 endotoxin Substances 0.000 description 8
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 8
• 229940096397 interleukin-8 Drugs 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• 201000008383 nephritis Diseases 0.000 description 8
• 230000011164 ossification Effects 0.000 description 8
• 239000013612 plasmid Substances 0.000 description 8
• 235000018102 proteins Nutrition 0.000 description 8
• 102000004169 proteins and genes Human genes 0.000 description 8
• 229920005989 resin Polymers 0.000 description 8
• 239000011347 resin Substances 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 238000007423 screening assay Methods 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 7
• 208000009304 Acute Kidney Injury Diseases 0.000 description 7
• 102000003952 Caspase 3 Human genes 0.000 description 7
• 108090000397 Caspase 3 Proteins 0.000 description 7
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
• 241000238631 Hexapoda Species 0.000 description 7
• QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 7
• QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 7
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
• VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 7
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
• 208000004608 Ureteral Obstruction Diseases 0.000 description 7
• 125000001931 aliphatic group Chemical group 0.000 description 7
• 125000000217 alkyl group Chemical group 0.000 description 7
• 230000000692 anti-sense effect Effects 0.000 description 7
• 229910002092 carbon dioxide Inorganic materials 0.000 description 7
• 210000003169 central nervous system Anatomy 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 208000020832 chronic kidney disease Diseases 0.000 description 7
• 230000008021 deposition Effects 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 229920006008 lipopolysaccharide Polymers 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 230000000921 morphogenic effect Effects 0.000 description 7
• 230000001575 pathological effect Effects 0.000 description 7
• 238000002823 phage display Methods 0.000 description 7
• 239000013641 positive control Substances 0.000 description 7
• 201000002793 renal fibrosis Diseases 0.000 description 7
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 6
• MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 6
• NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 6
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
• JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 6
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 6
• 241000588724 Escherichia coli Species 0.000 description 6
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 6
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 6
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
• AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 6
• KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 102000018120 Recombinases Human genes 0.000 description 6
• 108010091086 Recombinases Proteins 0.000 description 6
• 208000033626 Renal failure acute Diseases 0.000 description 6
• 108010077895 Sarcosine Proteins 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 208000006011 Stroke Diseases 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• 102000040945 Transcription factor Human genes 0.000 description 6
• 108091023040 Transcription factor Proteins 0.000 description 6
• 201000011040 acute kidney failure Diseases 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 235000003704 aspartic acid Nutrition 0.000 description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
• 230000017531 blood circulation Effects 0.000 description 6
• 150000001718 carbodiimides Chemical class 0.000 description 6
• 230000004663 cell proliferation Effects 0.000 description 6
• 230000036755 cellular response Effects 0.000 description 6
• 229940109239 creatinine Drugs 0.000 description 6
• 206010012601 diabetes mellitus Diseases 0.000 description 6
• 229960004679 doxorubicin Drugs 0.000 description 6
• 210000003527 eukaryotic cell Anatomy 0.000 description 6
• 210000002744 extracellular matrix Anatomy 0.000 description 6
• 239000012530 fluid Substances 0.000 description 6
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
• 206010061989 glomerulosclerosis Diseases 0.000 description 6
• 235000013922 glutamic acid Nutrition 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 238000000099 in vitro assay Methods 0.000 description 6
• 230000003834 intracellular effect Effects 0.000 description 6
• 230000000302 ischemic effect Effects 0.000 description 6
• 210000003716 mesoderm Anatomy 0.000 description 6
• 238000002703 mutagenesis Methods 0.000 description 6
• 231100000350 mutagenesis Toxicity 0.000 description 6
• 210000002569 neuron Anatomy 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 229910052760 oxygen Inorganic materials 0.000 description 6
• 230000000069 prophylactic effect Effects 0.000 description 6
• 238000000159 protein binding assay Methods 0.000 description 6
• 210000005084 renal tissue Anatomy 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 230000017423 tissue regeneration Effects 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 241000701447 unidentified baculovirus Species 0.000 description 6
• 239000004475 Arginine Substances 0.000 description 5
• 102000053602 DNA Human genes 0.000 description 5
• 102000005720 Glutathione transferase Human genes 0.000 description 5
• 108010070675 Glutathione transferase Proteins 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
• QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 5
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 5
• QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 5
• 206010061876 Obstruction Diseases 0.000 description 5
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 5
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 5
• 229920001213 Polysorbate 20 Polymers 0.000 description 5
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
• 239000004473 Threonine Substances 0.000 description 5
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 230000004075 alteration Effects 0.000 description 5
• 230000003510 anti-fibrotic effect Effects 0.000 description 5
• 230000000890 antigenic effect Effects 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 239000011324 bead Substances 0.000 description 5
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 238000004587 chromatography analysis Methods 0.000 description 5
• 229960002173 citrulline Drugs 0.000 description 5
• 235000013477 citrulline Nutrition 0.000 description 5
• 235000018417 cysteine Nutrition 0.000 description 5
• 230000003412 degenerative effect Effects 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 230000003176 fibrotic effect Effects 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 239000004220 glutamic acid Substances 0.000 description 5
• 238000002744 homologous recombination Methods 0.000 description 5
• 230000006801 homologous recombination Effects 0.000 description 5
• 210000004408 hybridoma Anatomy 0.000 description 5
• 239000007943 implant Substances 0.000 description 5
• 238000005462 in vivo assay Methods 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 208000037806 kidney injury Diseases 0.000 description 5
• 150000002611 lead compounds Chemical class 0.000 description 5
• 239000006166 lysate Substances 0.000 description 5
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
• 239000012139 lysis buffer Substances 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 210000004379 membrane Anatomy 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 210000004165 myocardium Anatomy 0.000 description 5
• 210000005036 nerve Anatomy 0.000 description 5
• 210000000287 oocyte Anatomy 0.000 description 5
• 229960003104 ornithine Drugs 0.000 description 5
• 230000002018 overexpression Effects 0.000 description 5
• 239000000816 peptidomimetic Substances 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
• 230000000750 progressive effect Effects 0.000 description 5
• 210000001236 prokaryotic cell Anatomy 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 5
• 238000001525 receptor binding assay Methods 0.000 description 5
• 238000011069 regeneration method Methods 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 4
• BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 4
• NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 4
• CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 4
• XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 206010005003 Bladder cancer Diseases 0.000 description 4
• 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 4
• 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 4
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 102000000844 Cell Surface Receptors Human genes 0.000 description 4
• 108010001857 Cell Surface Receptors Proteins 0.000 description 4
• 102000019034 Chemokines Human genes 0.000 description 4
• 108010012236 Chemokines Proteins 0.000 description 4
• 108091026890 Coding region Proteins 0.000 description 4
• 150000008574 D-amino acids Chemical class 0.000 description 4
• NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 4
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 4
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
• 206010028851 Necrosis Diseases 0.000 description 4
• 108091034117 Oligonucleotide Proteins 0.000 description 4
• 206010063837 Reperfusion injury Diseases 0.000 description 4
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
• 108010090804 Streptavidin Proteins 0.000 description 4
• 208000030886 Traumatic Brain injury Diseases 0.000 description 4
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 239000003098 androgen Substances 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000005754 cellular signaling Effects 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 210000001671 embryonic stem cell Anatomy 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 229960000310 isoleucine Drugs 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 150000002596 lactones Chemical class 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• VWHRYODZTDMVSS-QMMMGPOBSA-N m-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(F)=C1 VWHRYODZTDMVSS-QMMMGPOBSA-N 0.000 description 4
• 210000001161 mammalian embryo Anatomy 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 238000010172 mouse model Methods 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 208000010125 myocardial infarction Diseases 0.000 description 4
• 208000037891 myocardial injury Diseases 0.000 description 4
• 230000017074 necrotic cell death Effects 0.000 description 4
• 230000001537 neural effect Effects 0.000 description 4
• 210000004940 nucleus Anatomy 0.000 description 4
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• 230000004224 protection Effects 0.000 description 4
• 230000008439 repair process Effects 0.000 description 4
• 230000008458 response to injury Effects 0.000 description 4
• 238000007363 ring formation reaction Methods 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 239000013589 supplement Substances 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 230000009529 traumatic brain injury Effects 0.000 description 4
• 230000009452 underexpressoin Effects 0.000 description 4
• 201000005112 urinary bladder cancer Diseases 0.000 description 4
• 239000004474 valine Substances 0.000 description 4
• 210000003556 vascular endothelial cell Anatomy 0.000 description 4
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 3
• LNOLJFCCYQZFBQ-BUHFOSPRSA-N (ne)-n-[(4-nitrophenyl)-phenylmethylidene]hydroxylamine Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(=N/O)/C1=CC=CC=C1 LNOLJFCCYQZFBQ-BUHFOSPRSA-N 0.000 description 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 3
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 3
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 108010059616 Activins Proteins 0.000 description 3
• 108090000672 Annexin A5 Proteins 0.000 description 3
• 102000004121 Annexin A5 Human genes 0.000 description 3
• 108020005544 Antisense RNA Proteins 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 101710192393 Attachment protein G3P Proteins 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 102100026189 Beta-galactosidase Human genes 0.000 description 3
• 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 3
• 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 3
• 208000005623 Carcinogenesis Diseases 0.000 description 3
• 208000031229 Cardiomyopathies Diseases 0.000 description 3
• 208000024172 Cardiovascular disease Diseases 0.000 description 3
• 108010078791 Carrier Proteins Proteins 0.000 description 3
• 108050006400 Cyclin Proteins 0.000 description 3
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
• 230000004568 DNA-binding Effects 0.000 description 3
• QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 206010014561 Emphysema Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 241000233866 Fungi Species 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 239000007836 KH2PO4 Substances 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 208000001132 Osteoporosis Diseases 0.000 description 3
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 3
• 108700008625 Reporter Genes Proteins 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 238000002441 X-ray diffraction Methods 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000000488 activin Substances 0.000 description 3
• 238000001261 affinity purification Methods 0.000 description 3
• 238000013019 agitation Methods 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000000304 alkynyl group Chemical group 0.000 description 3
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 3
• 230000000844 anti-bacterial effect Effects 0.000 description 3
• 210000001367 artery Anatomy 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 150000001510 aspartic acids Chemical class 0.000 description 3
• 150000001540 azides Chemical class 0.000 description 3
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
• 108010005774 beta-Galactosidase Proteins 0.000 description 3
• 229940000635 beta-alanine Drugs 0.000 description 3
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 230000036952 cancer formation Effects 0.000 description 3
• 235000013877 carbamide Nutrition 0.000 description 3
• 231100000504 carcinogenesis Toxicity 0.000 description 3
• 230000022159 cartilage development Effects 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 230000007882 cirrhosis Effects 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 238000007906 compression Methods 0.000 description 3
• 230000006835 compression Effects 0.000 description 3
• 238000012937 correction Methods 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 239000013078 crystal Substances 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000010511 deprotection reaction Methods 0.000 description 3
• 238000003795 desorption Methods 0.000 description 3
• MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
• 230000010437 erythropoiesis Effects 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• 238000005755 formation reaction Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
• 238000001476 gene delivery Methods 0.000 description 3
• 150000002307 glutamic acids Chemical class 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 238000009396 hybridization Methods 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 238000001114 immunoprecipitation Methods 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 208000027866 inflammatory disease Diseases 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 102000006495 integrins Human genes 0.000 description 3
• 108010044426 integrins Proteins 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 210000003292 kidney cell Anatomy 0.000 description 3
• 201000006370 kidney failure Diseases 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000007791 liquid phase Substances 0.000 description 3
• 239000008267 milk Substances 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
• 235000019796 monopotassium phosphate Nutrition 0.000 description 3
• 230000002107 myocardial effect Effects 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• 239000002853 nucleic acid probe Substances 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 230000005305 organ development Effects 0.000 description 3
• 229960001639 penicillamine Drugs 0.000 description 3
• 230000003239 periodontal effect Effects 0.000 description 3
• 230000002974 pharmacogenomic effect Effects 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 239000000018 receptor agonist Substances 0.000 description 3
• 229940044601 receptor agonist Drugs 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000008929 regeneration Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 229940043230 sarcosine Drugs 0.000 description 3
• 238000013207 serial dilution Methods 0.000 description 3
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 239000011550 stock solution Substances 0.000 description 3
• 239000012089 stop solution Substances 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 235000011149 sulphuric acid Nutrition 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 230000030968 tissue homeostasis Effects 0.000 description 3
• 230000025934 tissue morphogenesis Effects 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 230000001131 transforming effect Effects 0.000 description 3
• 230000000472 traumatic effect Effects 0.000 description 3
• 230000008736 traumatic injury Effects 0.000 description 3
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 3
• 230000007306 turnover Effects 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 210000000626 ureter Anatomy 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 2
• BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
• YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 2
• OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
• YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
• UYWWLYCGNNCLKE-UHFFFAOYSA-N 2-pyridin-4-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=CC=NC=C1 UYWWLYCGNNCLKE-UHFFFAOYSA-N 0.000 description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 2
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
• XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• FAYOCELKCDKZCA-UHFFFAOYSA-N 5-hydroxy-2,4-dimethylthiophen-3-one Chemical compound CC1SC(O)=C(C)C1=O FAYOCELKCDKZCA-UHFFFAOYSA-N 0.000 description 2
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• 102000005606 Activins Human genes 0.000 description 2
• 208000030090 Acute Disease Diseases 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 2
• 244000186140 Asperula odorata Species 0.000 description 2
• 208000020084 Bone disease Diseases 0.000 description 2
• 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 2
• 108050008407 Bone morphogenetic protein receptor type-2 Proteins 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
• 229940126074 CDK kinase inhibitor Drugs 0.000 description 2
• 102000000905 Cadherin Human genes 0.000 description 2
• 108050007957 Cadherin Proteins 0.000 description 2
• 102000011727 Caspases Human genes 0.000 description 2
• 108010076667 Caspases Proteins 0.000 description 2
• 108010055166 Chemokine CCL5 Proteins 0.000 description 2
• 208000027205 Congenital disease Diseases 0.000 description 2
• 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
• 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 208000005189 Embolism Diseases 0.000 description 2
• 241000724791 Filamentous phage Species 0.000 description 2
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 102100039556 Galectin-4 Human genes 0.000 description 2
• 235000008526 Galium odoratum Nutrition 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• 208000010496 Heart Arrest Diseases 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 2
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 102000003777 Interleukin-1 beta Human genes 0.000 description 2
• 108090000193 Interleukin-1 beta Proteins 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 208000001738 Nervous System Trauma Diseases 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 208000037273 Pathologic Processes Diseases 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
• 108700005078 Synthetic Genes Proteins 0.000 description 2
• 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 description 2
• 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 241000700618 Vaccinia virus Species 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 208000012998 acute renal failure Diseases 0.000 description 2
• 229940072056 alginate Drugs 0.000 description 2
• 150000001335 aliphatic alkanes Chemical class 0.000 description 2
• 125000005907 alkyl ester group Chemical group 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000003862 amino acid derivatives Chemical class 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000000843 anti-fungal effect Effects 0.000 description 2
• 239000000868 anti-mullerian hormone Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 229940034982 antineoplastic agent Drugs 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 238000003782 apoptosis assay Methods 0.000 description 2
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 239000003637 basic solution Substances 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 239000013060 biological fluid Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 210000002805 bone matrix Anatomy 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 230000005779 cell damage Effects 0.000 description 2
• 230000003822 cell turnover Effects 0.000 description 2
• 230000033077 cellular process Effects 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 210000004268 dentin Anatomy 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 229940028334 follicle stimulating hormone Drugs 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 230000004217 heart function Effects 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 150000002463 imidates Chemical class 0.000 description 2
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 238000012744 immunostaining Methods 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000010874 in vitro model Methods 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000000266 injurious effect Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000004255 ion exchange chromatography Methods 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 230000003907 kidney function Effects 0.000 description 2
• 150000003951 lactams Chemical class 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 238000004811 liquid chromatography Methods 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 238000005374 membrane filtration Methods 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 210000000944 nerve tissue Anatomy 0.000 description 2
• 208000028412 nervous system injury Diseases 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 230000005937 nuclear translocation Effects 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 230000008816 organ damage Effects 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 230000033116 oxidation-reduction process Effects 0.000 description 2
• IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
• 239000004031 partial agonist Substances 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000009054 pathological process Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 208000028169 periodontal disease Diseases 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 230000004983 pleiotropic effect Effects 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 230000005522 programmed cell death Effects 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
• 201000001474 proteinuria Diseases 0.000 description 2
• 210000005234 proximal tubule cell Anatomy 0.000 description 2
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 238000011552 rat model Methods 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 208000017443 reproductive system disease Diseases 0.000 description 2
• 238000002821 scintillation proximity assay Methods 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000006104 solid solution Substances 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• 210000004926 tubular epithelial cell Anatomy 0.000 description 2
• 210000005239 tubule Anatomy 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
• BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
• PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
• HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• BWKMGYQJPOAASG-UHFFFAOYSA-M 1,2,3,4-tetrahydroisoquinoline-3-carboxylate Chemical compound C1=CC=C2CNC(C(=O)[O-])CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-M 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
• MPBMJFQAGBVIDC-UHFFFAOYSA-N 1-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2C(O)NC(C(O)=O)CC2=C1 MPBMJFQAGBVIDC-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• JPHGTWWUDOEBRJ-UHFFFAOYSA-N 2-amino-3,4,4a,5-tetrahydro-1h-naphthalene-2-carboxylic acid Chemical compound C1C=CC=C2CC(N)(C(O)=O)CCC21 JPHGTWWUDOEBRJ-UHFFFAOYSA-N 0.000 description 1
• 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 102100034111 Activin receptor type-1 Human genes 0.000 description 1
• 102100034134 Activin receptor type-1B Human genes 0.000 description 1
• 101710173011 Activin receptor type-1B Proteins 0.000 description 1
• 102100034135 Activin receptor type-1C Human genes 0.000 description 1
• 101710173005 Activin receptor type-1C Proteins 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 206010001580 Albuminuria Diseases 0.000 description 1
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
• 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 239000011547 Bouin solution Substances 0.000 description 1
• COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 240000001432 Calendula officinalis Species 0.000 description 1
• 235000005881 Calendula officinalis Nutrition 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 108091029430 CpG site Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 241000702191 Escherichia virus P1 Species 0.000 description 1
• 108010040476 FITC-annexin A5 Proteins 0.000 description 1
• 108010046276 FLP recombinase Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 102000002068 Glycopeptides Human genes 0.000 description 1
• 108010015899 Glycopeptides Proteins 0.000 description 1
• VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
• 241000288105 Grus Species 0.000 description 1
• 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
• 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
• 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 1
• 101000800679 Homo sapiens Testis development-related protein Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102100026818 Inhibin beta E chain Human genes 0.000 description 1
• 108010004250 Inhibins Proteins 0.000 description 1
• 102000002746 Inhibins Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 206010059491 Intracranial haematoma Diseases 0.000 description 1
• 206010023421 Kidney fibrosis Diseases 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 239000012901 Milli-Q water Substances 0.000 description 1
• 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
• 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 108700028031 Myelin Basic Proteins 0.000 description 1
• 108010056852 Myostatin Proteins 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 108010079364 N-glycylalanine Proteins 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 208000008457 Neurologic Manifestations Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• NLLHXVBITYTYHA-UHFFFAOYSA-N Nitrofor Chemical compound CCN(CC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O NLLHXVBITYTYHA-UHFFFAOYSA-N 0.000 description 1
• 108010051791 Nuclear Antigens Proteins 0.000 description 1
• 102000019040 Nuclear Antigens Human genes 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 101001076459 Rattus norvegicus Interleukin-6 Proteins 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 108050002653 Retinoblastoma protein Proteins 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 108091006627 SLC12A9 Proteins 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
• 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 102000007374 Smad Proteins Human genes 0.000 description 1
• 108010007945 Smad Proteins Proteins 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000032760 Subdural Intracranial Hematoma Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
• 102100033675 Testis development-related protein Human genes 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000005299 abrasion Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 238000009167 androgen deprivation therapy Methods 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000002506 anticoagulant protein Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000007860 aryl ester derivatives Chemical class 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 230000008267 autocrine signaling Effects 0.000 description 1
• 239000013602 bacteriophage vector Substances 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 239000012148 binding buffer Substances 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 210000001109 blastomere Anatomy 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 231100001015 blood dyscrasias Toxicity 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 125000005997 bromomethyl group Chemical group 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000009702 cancer cell proliferation Effects 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 206010007625 cardiogenic shock Diseases 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 238000012219 cassette mutagenesis Methods 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 101150073031 cdk2 gene Proteins 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 210000004720 cerebrum Anatomy 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 230000014564 chemokine production Effects 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 230000009816 chondrogenic differentiation Effects 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 208000035850 clinical syndrome Diseases 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000002742 combinatorial mutagenesis Methods 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000013601 cosmid vector Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 238000012303 cytoplasmic staining Methods 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
• 150000001982 diacylglycerols Chemical class 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 201000000523 end stage renal failure Diseases 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000008753 endothelial function Effects 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 229960003699 evans blue Drugs 0.000 description 1
• 238000011124 ex vivo culture Methods 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 238000002875 fluorescence polarization Methods 0.000 description 1
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000001434 glomerular Effects 0.000 description 1
• 231100000852 glomerular disease Toxicity 0.000 description 1
• 230000024924 glomerular filtration Effects 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 150000002332 glycine derivatives Chemical class 0.000 description 1
• 239000007986 glycine-NaOH buffer Substances 0.000 description 1
• VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 210000001308 heart ventricle Anatomy 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 239000008241 heterogeneous mixture Substances 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 238000006698 hydrazinolysis reaction Methods 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
• 238000002169 hydrotherapy Methods 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 230000009848 hypophosphorylation Effects 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000000893 inhibin Substances 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• XAAKCCMYRKZRAK-UHFFFAOYSA-N isoquinoline-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NC=CC2=C1 XAAKCCMYRKZRAK-UHFFFAOYSA-N 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 210000000738 kidney tubule Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 238000000670 ligand binding assay Methods 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 230000006667 mitochondrial pathway Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004001 molecular interaction Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 230000001002 morphogenetic effect Effects 0.000 description 1
• 210000000472 morula Anatomy 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• 201000002674 obstructive nephropathy Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
• 238000006213 oxygenation reaction Methods 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 230000014306 paracrine signaling Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 238000000059 patterning Methods 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000002379 periodontal ligament Anatomy 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 108010079892 phosphoglycerol kinase Proteins 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 150000003053 piperidines Chemical class 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 238000012342 propidium iodide staining Methods 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 230000009979 protective mechanism Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 239000012474 protein marker Substances 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 238000003653 radioligand binding assay Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 238000002278 reconstructive surgery Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000003938 response to stress Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 230000007781 signaling event Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 230000008410 smoothened signaling pathway Effects 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 210000001258 synovial membrane Anatomy 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 238000003161 three-hybrid assay Methods 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000009772 tissue formation Effects 0.000 description 1
• 229950003937 tolonium Drugs 0.000 description 1
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 229910052723 transition metal Inorganic materials 0.000 description 1
• 150000003624 transition metals Chemical class 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 125000006000 trichloroethyl group Chemical group 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 230000010024 tubular injury Effects 0.000 description 1
• 208000037978 tubular injury Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000005760 tumorsuppression Effects 0.000 description 1
• 238000003160 two-hybrid assay Methods 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 210000004127 vitreous body Anatomy 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1